Life Science Investing Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Life Science Investing Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
Life Science Investing Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
RZOLV Technologies Announces Independent SGS Lab-Scale Test Results on Gravity Concentrates - 98.7% Gold Recoveries
RZOLV Technologies Announces Independent SGS Lab-Scale Test Results on Gravity Concentrates - 98.7% Gold Recoveries
NextSource Materials Executes Term Sheets with Strategic Investors and Local Capital Partners to Advance Towards Final Investment Decision for its Proposed UAE Battery Anode Facility
